Myriad Genetics (MYGN) EBIT (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of EBIT data on file, last reported at -$30.7 million in Q1 2026.

• EBIT for Q1 2026 came in at -$30.7 million, down 5.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$388.9 million (down 212.37% YoY), and the FY2025 annual result was -$387.2 million, down 213.52% from the prior year.
• EBIT slipped to -$30.7 million in Q1 2026 per MYGN's latest filing, from -$5.7 million in the prior quarter.
• Over five years, EBIT peaked at -$5.7 million in Q4 2025 and troughed at -$329.2 million in Q2 2025.
• A 5-year average of -$55.3 million and a median of -$31.4 million in 2023 frame the typical range for EBIT.
• On a YoY basis, EBIT climbed as much as 85.38% in 2025 and fell as far as 801.92% in 2025.
• A 5-year view of EBIT shows it stood at -$52.2 million in 2022, then surged by 39.85% to -$31.4 million in 2023, then dropped by 24.2% to -$39.0 million in 2024, then soared by 85.38% to -$5.7 million in 2025, then sank by 438.6% to -$30.7 million in 2026.
• Business Quant data shows MYGN's EBIT at -$30.7 million in Q1 2026, -$5.7 million in Q4 2025, and -$23.3 million in Q3 2025.